The Use of the Long-Acting Somatostatin Analogue, Octreotide Acetate, in Patients with Islet Cell Tumors

摘要: SUMMARY Octreotide lowers plasma concentrations of the marker peptide in majority patients with islet cell tumors (Fig. 3). However, as described above effect octreotide on peptides is not necessarily related to symptoms. Nevertheless capable producing symptomatic relief a large proportion tumor syndromes 4). The data symptoms due VIPoma and carcinoid syndrome (presumably including some who have tumors) are strong drug has been approved for these indications by Food Drug Administration. With respect other syndromes, published suggest that utility differs different syndromes. Insulinomas usually single, benign, can should be removed surgically, resulting cure. therefore no role play such patients, particularly since response insulinomas variable. However 10 per cent malignant certainly effective at least portion cases, although yet true rate efficacy compared diazoxide clear. Although reducing acid output, thus improving Zollinger-Ellison syndrome, because effectiveness histamine H2-receptor antagonists omeprazole, there need this syndrome. For glucagonoma, GHRHoma, Cushing’s rare may well benefit considered. current do support use an antitumor effect.